Tang Rui

Tang Rui

Tang Rui is the name of a drug. Metformin can not effectively control hyperglycemia in patients with type 2 diabetes. Metformin combined with metformin can not replace metformin.

Name: nateglinide tablets

indication

This product can be used alone in patients with type 2 diabetes who can not effectively control hyperglycemia through diet and exercise, and can also be used in patients with type 2 diabetes who can not effectively control hyperglycemia by using metformin. It can be used in combination with metformin, but it can not replace metformin. Nateglinide is not suitable for patients with type 2 diabetes mellitus who are not treated well by sulfonylureas.

administration and dosage

Oral administration. Generally, adults take 60-120mg (2-4) tablets three times a day within 1-15 minutes before meals. It is recommended to start from a small dose and adjust the dose according to the results of regular HBAIC or 1-2 hours postprandial blood glucose test. The dose can be gradually increased to 180mg (6 tablets) each time. dosage of patients with liver damage: there is no need to adjust the dosage of nateglinide in patients with mild to moderate liver disease. Compared with healthy people, the difference in bioavailability and half-life of nateglinide in patients with mild to moderate liver disease does not reach the degree of clinical significance. The medication situation of patients with severe liver disease has not been studied, so patients with severe liver disease should be cautious in using nateglinide. dosage of patients with renal damage: there is no need to adjust the dosage of nateglinide in patients with renal damage. In patients with moderate to severe renal insufficiency (creatinine clearance rate 15-50ml / min / 1.73m2) and patients requiring dialysis, the difference in bioavailability and half-life between nateglinide and healthy people does not reach the degree of clinical significance.

Adverse reactions

1. Hypoglycemia: like other antidiabetic drugs, symptoms of hypoglycemia can be observed after taking nateglinide, including sweating, shaking, dizziness, loss of appetite, palpitations, nausea, fatigue and weakness. These symptoms are generally mild and manageable, and carbohydrates are available if needed. Clinical research reports showed hypoglycemia symptoms, and confirmed that the proportion of patients with hypoglycemia (blood glucose < 3.3 mmol / L) was 7.69%; 2. Liver function: very few patients had increased liver enzymes, which was mild and transient, and rarely led to drug withdrawal; 3. Allergy: very few reports of allergic reactions such as rash, pruritus and urticaria; 4. Other reactions: including gastrointestinal reactions (abdominal pain) In addition, the levels of lactic acid, pyruvic acid, uric acid and serum potassium increased.

taboo

Nateglinide is forbidden in the following patients: 1. Allergic to the active ingredient of the drug or any excipient; 2. Type 2 diabetes mellitus (insulin-dependent diabetes mellitus); 3. Diabetic ketoacidosis.

matters needing attention

1. Hypoglycemia: This product can cause hypoglycemia. The frequency of hypoglycemia is related to the severity of diabetes, the level of blood glucose control, and other related conditions of the patient. Elderly patients, malnourished patients and patients with adrenal or pituitary dysfunction are more sensitive to hypoglycemic drugs and prone to hypoglycemia. The risk of hypoglycemia was increased when strenuous exercise, drinking, diarrhea and vomiting, eating less, or combined with other antidiabetic drugs. It is difficult to recognize hypoglycemia in patients with autonomic neuropathy or combined use of beta blockers. Nateglinide must be taken orally before meals to reduce the risk of hypoglycemia. Patients should not take nateglinide when they are not ready to eat. 2. It should be used with caution in patients with moderate or severe liver function damage. 3. Abnormal blood glucose control: when the patient is accompanied by fever, infection, trauma or operation, blood glucose can rise temporarily. Insulin should be used instead of nateglinide. After using nateglinide for a period of time, it can cause secondary failure or efficacy weakening. Patients with severe infection, before and after operation or severe trauma should be cautious. 4. This product can rapidly promote insulin secretion. The action point is the same as that of sulfonylureas. However, the clinical effect and safety of this product and sulfonylureas have not been confirmed, so it can not be used together with sulfonylureas. 5. Combination with other oral antidiabetic drugs can increase the risk of hypoglycemia. 6. Patients should be reminded to take preventive measures to avoid hypoglycemia when driving or operating the machine. Blood glucose should be detected regularly.